A new class action in Michigan federal court accuses pharmaceutical company Allergan of hiding information that its breast implants were linked to a rare form of cancer, Law360 reports.
Six women filed a proposed class action against Allergan on Tuesday, Nov. 26, alleging Allergan “buried” reports of serious injuries by filing them as “alternative summary reports” instead of in the U.S. Food and Drug Administration’s public database. The problems only came to light, the women said, when the FDA stopped using those reports in 2017.
When the FDA demanded more rigorous reporting requirements, the number of adverse events related to breast implants went up from 200 to 4,567 in 2017 and 8,242 in the first half of 2018, as reported by Law360.
The lawsuit claims Allergan had evidence since at least 2006 that its Biocell textured breast implants imposed significant risk of a blood cancer called anaplastic large cell lymphoma, or BIA-ALCL.
Allergan announced a global recall of the Biocell implants in July 2019 after the FDA put pressure on the company to take the implants off the US market. The company is apparently offering replacement implants for women who have Biocell, Allergan is not paying for any associated costs, including the cost of surgery, according to the lawsuit.
As part of the lawsuit, the women are seeking to have Allergan fund a medical monitoring program that detects diseases, especially BIA-ALCL.
Similar lawsuits have been filed against Allergan since the July recall, including one in Illinois.
If you were implanted with an Allergan Biocell textured breast implant, you may be entitled to financial compensation. The attorneys at Schmidt National Law Group are now accepting cases from women implanted with Allergan’s Biocell implants.
Call us at 800-631-5656 today to speak with a member of our legal team and see if you qualify for an Allergan Breast Implant Cancer Lawsuit.